Hansa Biopharma announced positive results from the European PAES study of Idefirix (imlifidase), showing 90% graft failure-free survival at 1 year in highly sensitized kidney transplant patients. The treatment enabled transplantation in patients with positive crossmatch against deceased donors, a group typically hard to transplant. Patient and graft survival rates were 98% and 92%, respectively, with good kidney function and manageable safety profile. These findings support Idefirix's potential to address unmet needs in kidney transplantation for highly sensitized patients.
Hansa Biopharma's positive Idefirix PAES results provide context for readers interested in health-sector stocks. As of Oct 24, 2026 00:21 WIB, out of 150 priced US health-sector stocks tradable on Pluang, 47 rose and 103 fell. Notable movers include TVTX at USD 50.41 with a 1-day change of -3.85%, BNGO at USD 1.14 with a 1-day change of -3.81% and Pluang order activity of 77% Buy, and GH at USD 169.12 with a 1-day change of +3.79% but 100% Sell order activity. The most notable figure is the 103 stocks that fell today in this sector.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
